Why Option Care Health (OPCH) Stock Is Trading Up Today
Option Care Health (OPCH) shares surged 33.2% pre-market after reports of a potential $5B+ acquisition by McKesson and Clayton Dubilier & Rice. The company's revenue grew 1.3% YoY to $1.35B in Q1 2026, missing estimates, with adjusted EPS of $0.40. Full-year revenue guidance was lowered to $5.73B, below analyst expectations.
How this was made
The 30-second read
Why it matters
The reported near‑term acquisition talks have already moved the stock 33% higher, indicating strong market sensitivity to M&A news in the health‑care services space.
Market read
The acquisition rumor creates immediate upside for OPCH and may trigger broader sector re‑rating.
What to watch
Regulatory approval risk and integration challenges could temper the upside.
Background
Option Care Health provides infusion services; McKesson is a major pharmaceutical distributor; Clayton Dubilier & Rice is a private‑equity firm.
Ticker impact
Shares jumped 33.2% pre‑market after report that McKesson and Clayton Dubilier & Rice are near a $5B acquisition of Option Care Health.
upward pressure as investors price in a potential takeover premium
A $5B buyout at a premium typically lifts the target's share price; the 33% pre‑market move confirms market reaction.
Market effects
Potential consolidation in the infusion services and specialty health‑care sector could lift peers.
U.S. healthcare services market may see increased M&A activity.
Large‑cap buyers like McKesson signal continued appetite for strategic health‑care acquisitions worldwide.
Counterpoint
If the deal falls through, the recent price surge could reverse sharply.
Key entities
- CompanyOption Care Health
NASDAQ‑listed infusion services provider (OPCH).
- CompanyMcKesson
Large U.S. pharmaceutical distributor and potential acquirer.
- Private‑Equity FirmClayton Dubilier & Rice
Partner in the proposed acquisition.
